Skip to main content
Explore URMC

Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

Basic Study Information

This is an international, multi-center, double-blind, placebo-controlled evaluation valganciclovir treatment for up to 54 children (up to 4 years of age) with virologically-confirmed congenital CMV infection and hearing loss. Subject participation will be over a six-month period and study subjects will be stratified according to age. The primary objective is to assess whether a six-week course of oral valganciclovir can stabilize the hearing of children with congenital CMV infection who present with hearing loss.

Study Contact Information

Study Coordinator: David W Kimberlin
Phone: 12059345316

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search